Jacobs Levy Equity Management’s Neuronetics STIM Stock Holding History

Jacobs Levy Equity Management’s Portfolio STIM Stock Details STIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,944	Closed	-$88K	–	1084
2022 Q1	$88K	Sell	28,944 -145,104	-83%	-$490K	﹤0.01%	982
2021 Q4	$776K	Sell	174,048 -27,883	-14%	-$137K	0.01%	781
2021 Q3	$1.32M	Buy	201,931 +172,987	+598%	+$1.66M	0.01%	694
2021 Q2	$464K	Hold	28,944	–	–	﹤0.01%	877
2021 Q1	$358K	Sell	28,944 -55,486	-66%	-$851K	﹤0.01%	910
2020 Q4	$938K	Sell	84,430 -136,454	-62%	-$1.03M	0.01%	740
2020 Q3	$1.07M	Buy	+220,884	New	+$838K	0.01%	649
2020 Q1	–	Sell	-143,946	Closed	-$646K	–	1090
2019 Q4	$646K	Buy	+143,946	New	+$894K	0.01%	753

Other funds holding STIM

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

MAG

Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Jacobs Levy Equity Management's STIM Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Neuronetics (STIM) in Q2 2022, closing a stake of 28,944 shares — an estimated $88K sold.

Jacobs Levy Equity Management first reported a position in STIM in Q4 2019 and held it in 8 quarters. The position peaked at $1.32M in Q3 2021. 77 funds tracked by Wall St. Rank hold STIM as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Neuronetics position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 28,944 Neuronetics shares in Q2 2022, an estimated $88K.
Jacobs Levy Equity Management first reported a position in Neuronetics in Q4 2019 and held it in 8 quarters.
Jacobs Levy Equity Management's Neuronetics position peaked at $1.32M in Q3 2021.
77 funds tracked by Wall St. Rank held Neuronetics as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.